Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

plications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future intellectual property litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc. Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has selected an optimized Erk inhibitor molecule for ... development of a new class of potential cancer ... a prime target for therapeutic intervention in cancer. ... survival benefits for B-Raf and Mek inhibitors. Erk ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... (BI) advanced cell culture products, announces the availability of BI’s line of human ... Biological Industries, these stem cell differentiation media offer a complete system for multipotency ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density ... than 12,000 mPas (internal air) up to 36,000 (external air) – and can process up ... Xsample 530 is its removable magazine, which is easily lifted off its hub and carried ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Ikaria, Inc., a critical care company focused on developing ... needs of critically ill patients in the hospital and ... Daniel Tasse, will present at the 2011 Biotechnology Industry ... given on Tuesday, October 25, 2011 from 11:30 to ...
... 2011 The EORTC, BIG, and Agendia, a ... patient registration for the EORTC 10041/BIG3-04 MINDACT ( M icroarray ... lymph node D isease may A void ... in 111 institutions across nine countries were enrolled from February ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and ... the board increased the number of directors on the ... meeting and appointed Mr. Zack Zibing Pan to its ...
Cached Biology Technology:Ikaria® to Present at 2011 BIO Investor Forum 2EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 2EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 3EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 4EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 5China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 2China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 3
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... about the most stressful thing that can happen to anybody. ... list of traumatic experiences. Most humans come to terms with ... How weaning takes place, however, can have a dramatic effect ... That this is so, at least for horses, comes from the ...
... 2011 -- Directly advertising food items to children worries ... Academy of Pediatrics and the American Psychological Association have ... children,s healthy food choices. A new study soon ... explores the relationship between fast food advertisements, parental ...
... Large, persistent populations of genetically engineered canola ... North Dakota. As genetically engineered crops become increasingly ... potential ecological side effects. A study published ... reports that genetically engineered canola endowed with ...
Cached Biology News:The short goodbye: Weaning foals 2The short goodbye: Weaning foals 3Study suggests children's food choices are affected by direct advertising and parental influence 2
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Silica bead method is an economic method of DNA extraction from agarose...
5 minutes from gel band to purified DNA...
Biology Products: